From:  Immune checkpoint inhibitors in patients with advanced gastric cancer: a multi-institutional retrospective real-world study

Patient characteristics according to NLR

Risk factor and categoryNLR < 1.8
n, (%)		NLR ≥ 1.8
n, (%)		P
All2447
Age< 65
≥ 65		8 (33)
16 (67)		26 (55)
21 (45)		0.079
GenderMale
Female		17 (71)
7 (29)		28 (60)
19 (40)		0.352
ECOG0–1
2–3		18 (75)
6 (25)		23 (49)
24 (51)		0.035
Histology gradeG1–G2
G3
NA		7 (29)
16 (67)
1 (4)		17 (36)
26 (55)
4 (9)		0.464
MSI statusMSI-H
MSS
NA		6 (25)
13 (54)
5 (21)		8 (17)
29 (62)
10 (21)		0.716
Signet-ring cell carcinomaYes
No
NA		3 (13)
6 (25)
15 (62)		13 (27)
9 (20)
25 (53)		0.193
Primary tumorPresence
Surgical removal		10 (42)
14 (58)		34 (72)
13 (28)		0.012
Number of organs with metastases1–2
≥ 3		22 (92)
2 (8)		27 (57)
20 (43)		0.003
AscitesYes
No		9 (37)
15 (63)		28 (60)
19 (40)		0.078
Peritoneal carcinomatosisYes
No		11 (46)
13 (54)		30 (64)
17 (36)		0.146
Bone metastasesYes
No		1 (4)
23 (96)		7 (15)
40 (85)		0.176
PainYes
No		8 (33)
16 (67)		24 (51)
23 (49)		0.156
Line of immunotherapyI–II
III–IV		13 (54)
11 (46)		19 (40)
28 (60)		0.271
Return to article view

NLR: neutrophil-lymphocyte ratio; ECOG: Eastern Cooperative Oncology Group; MSI: microsatellite instability; MSI-H: high microsatellite instability; MSS: microsatellite stable; NA: not available